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Using metformin in the presence of renal disease
Current guidelines are too restrictive, and many patients who could benefit are missing out
Tahseen A Chowdhury consultant in diabetes, Roisin Wright lead diabetes nurse, M Magdi Yaqoob
professor in clinical nephrology
Departments of Diabetes and Nephrology, Barts and the London School of Medicine and Dentistry, London E1 1BB, UK.
In January, the electronic Medicines Compendium (eMC)
updated the Summary of Product Characteristics for Glucophage
(metformin), approved by the UK Medicines and Healthcare
Products Regulatory Agency (MHRA). The summary states
that “Metformin may be used in patients with moderate renal
impairment, stage 3a (creatinine clearance [CrCl] 45-59mL/min
or estimated glomerular filtration rate [eGFR] 45-59
mL/min/1.73 m2) only in the absence of other conditions that
may increase the risk of lactic acidosis . . . If CrCl or eGFR fall
<45 mL/min or <45 mL/min/1.73 m2 respectively, metformin
must be discontinued immediately.”1 This is reiterated in the
patient information leaflet.
Interestingly, the summary for generic metformin states that
“Renal failure or renal dysfunction (creatinine clearance <60
ml/min)” is a contraindication to use. In the face of burgeoning
levels of type 2 diabetes and associated renal disease, we believe
that this restriction is too conservative and will deny an
important drug to many thousands of people with diabetes who
are likely to benefit from its important clinical effects and have
few alternative treatments.
Metformin is recommended as the first line oral hypoglycaemic
drug for patients with type 2 diabetes in national and
international guidelines.2 3 The drug is the only one of many
diabetes drugs to show cardiovascular benefits, especially in
overweight or obese patients with type 2 diabetes.4 Metformin
is also useful in overweight patients with type 1 diabetes,5
womenwith gestational diabetes or polycystic ovary syndrome,6
and in people at high risk of developing diabetes.7 There is some
epidemiological evidence that metformin may reduce the risk
of cancer in people with type 2 diabetes.8 The drug has been
safely and widely prescribed for over 50 years and benefited
millions of people. The adverse gastrointestinal effects of
metformin are usually mild and temporary, and the drug does
not induce weight gain. Use of metformin with insulin is both
insulin dose sparing and weight sparing.
Risk of lactic acidosis overstated
Around a quarter of all patients with type 2 diabetes develop
diabetic nephropathy, and the condition is the commonest cause
of end stage renal failure in most developed countries. The
concerns over metformin and renal impairment arise from the
perceived risk of lactic acidosis in such patients. Although
metformin overdose may be linked with lactic acidosis, a recent
systematic review of cases reporting a link between metformin
and lactic acidosis suggests no direct causal link and that other
factors (such as sepsis or hepatic or cardiac failure) may be
implicated.9 Indeed, a Cochrane review on the subject concluded
that there is no evidence from prospective or observational
studies that metformin is associated with lactic acidosis, nor
even associated with raised lactate concentrations.10 This is
supported by a review of the General Practice Research
Database, which showed a crude rate of lactic acidosis of 3.3
per 100 000 patient years among people taking metformin,
compared with 4.8 per 100 000 patient years among those taking
sulfonylurea.11
Nevertheless, the relatively unfounded concerns mean that large
numbers of patients with type 2 diabetes are not receiving
metformin, and indeed this number could grow if pharmaceutical
guidelines are adhered to. A recent survey in the US suggests
that if all patients with diabetes and eGFR >30 mL/min/1.73
m2were prescribed metformin, roughly one million more people
would be taking the drug.12
Wider use
Premature cessation of metformin in patients with renal disease
may expose them to considerable harm. In clinical practice, we
often see premature cessation of metformin leading to poor
glucose control, and further deterioration in renal function.
Diabetic patients with renal disease have a higher cardiovascular
risk, and denying them metformin may increase this risk.
Although several new drugs are available for use in people with
type 2 diabetes, most are contraindicated or not licensed for use
in renal impairment. Glitazones are associated with weight gain,
fluid retention, heart failure, and possibly postmenopausal
fractures. Saxagliptin is associated with heart failure, and
sulfonylureas and insulin are associated with hypoglycaemia
andweight gain—adverse effects that are particularly concerning
in patients with renal disease.
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Guidelines from the UK National Institute for Health and
Clinical Excellence (NICE) suggest that metformin dose should
be reviewed at an eGFR of 45 and stopped at an eGFR of 30.2
There is accumulating evidence, however, to suggest an
important pharmacogenetic component to metformin
metabolism, and this may enable some patients to continue the
drug at lower levels of renal function.13 Dosing may be guided
by wider use of plasma metformin concentrations in such
patients, although further research evidence is required before
this practice can be advocated. Nevertheless, NICE guidelines
are pragmatic and can safely be used in clinical practice. We
would encourage clinicians to use these guidelines and reassure
patients that metformin is perfectly safe in stable renal disease.
Patients should, however, be advised to stop metformin during
periods of acute illness (such as gastrointestinal upset or other
infections), where renal function may acutely deteriorate, and
restart metformin when they have recovered.
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